RNA Pol II Inhibitor-Bacteria is under clinical development by Hamlet Pharma and currently in Phase I for Inflammation.

致力于开发创新疗法的临床阶段制药公司 Ractigen Therapeutics 宣布，美国食品药品监督管理局 (FDA) 已授予其针对 FUS 基因的新型 siRNA 疗法 RAG-21 孤儿药资格 (ODD) ，用于治疗肌萎缩侧索硬化症 (ALS ...

Quantum computing and biotech companies are testing whether next-generation computing technology could help them develop ...

These signals are part of the intricate coordination of immune responses against virus invasion. With RNA increasingly seen as both a drug and a druggable target, the new findings open the potential ...

Scientists have uncovered a new role for a cell's own RNA in fending off attacks by RNA viruses. Some of the cell's RNA ...

Optimizing Lead Discovery, Structural Analysis & Preclinical Modeling to Successfully Develop Stable, Effective & Orally Bioavailable Small Molecule RNA Drugs for Robust Translation into the ...

RNA in cells performs an astounding number of functions. Messenger RNA carries the sequences of active genes to the cellular machinery, which turns... | Cell And Molecular Biology ...

Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine, St. Louis, USA ...

Filed provisional patent application, further expanding IP portfolio ...

LAUSANNE, Switzerland--(BUSINESS WIRE)--Alithea Genomics, a leader in the field of large-scale RNA sequencing and transcriptomics, announced today the launch of MERCURIUS™ Full-Length DRUG-seq ...